In addition, it explores emerging strategies for integrating ALK inhibitors into precision-based management of T-cell lymphomas, including combination approaches with chemotherapy, immunotherapy or antibody-drug conjugates. This evidence concerns the gene ALK and T-cell non-Hodgkin lymphoma.